ANN ARBOR, MI / ACCESSWIRE / November 22, 2017 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, has been invited to present at the 10th Annual LD Micro Main Event being held on December 5-7, 2017, at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
ENDRA Life Sciences CEO, Francois Michelon, and CFO, David Wells, are scheduled to present on Wednesday, December 6th, at 10:30 a.m. Pacific Time, with one-on-one meetings held throughout the conference.
For additional information or to schedule a one-on-one meeting with ENDRA management, please log-in via the link provided in your invitation. You may also email your request to NDRA@mzgroup.us or call Chris Tyson at (949) 491-8235.
View ENDRA Life Sciences Inc.'s profile here: http://www.ldmicro.com/profile/NDRA.
News Compliments of ACCESSWIRE.
About the 10th Annual LD Micro Main Event
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe. It is a non-registered investment advisor. For more details, please click here.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA) is a developer of enhanced ultrasound technologies. ENDRA's Photo-Acoustic Nexus-128 system is currently used by leading global medical researchers to screen and modify disease models with high image quality and volume scanning speed. ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound ("TAEUS") system to enable clinicians to visualize human tissue composition, function, and temperature in ways previously possible only on CT & MRI - at a fraction of the cost, and at the point-of-care. ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally. ENDRA's goal is to bring new capabilities to ultrasound - thereby broadening access to better healthcare. For more information, please visit www.endrainc.com.
Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com
Media & Investor Relations Contact:
MZ North America
Chris Tyson
Managing Director
(949) 491-8235
NDRA@mzgroup.us
www.mzgroup.us
SOURCE: ENDRA Life Sciences Inc.